Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 8/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19181227 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL13163960 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL21770659 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL29231967 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL29246157 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL1604238 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL1584687 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL30104010 | 0.91 | NR1H2 (0.44) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL24251931 | 0.88 | NR1H2 (0.40) | NR1H2UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL24739166 | 0.88 | NR1H2 (0.47) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4219478-B1 | METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-115698020-B | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2025-02-25 | — | — | CN | disclosed |
| US-20160235746-A1 | Novel Amino Pyrimidine Derivatives | NOVARTIS AG (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9278996-B2 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | CELLTRION, INC. (KR) | 2016-03-08 | — | — | US | disclosed |
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | CELLTRION, INC. (KR) | 2015-08-13 | — | — | US | disclosed |
| EP-2889287-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | Celltrion, Inc. (KR) | 2015-07-01 | — | — | EP | disclosed |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2708540-A1 | PYRIMIDO-DIAZEPINONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | DAD1, DDOST, SCD5 | NR1H2 258/4885SRC 3232/4885UCHL1 4640/4885 |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | BTK, LCK, JAK1 | NR1H2 3676/4885SRC 22/4885UCHL1 4717/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | NR1H2 1715/4885SRC 106/4885UCHL1 3052/4885 |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | NR1H2 666/4885SRC 3607/4885UCHL1 4316/4885 |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | NR1H2 167/4885SRC 3102/4885UCHL1 3129/4885 |
| US-20160235746-A1 | Novel Amino Pyrimidine Derivatives | BTK, LCK, JAK1 | NR1H2 3676/4885SRC 22/4885UCHL1 4717/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | NR1H2 804/4885SRC 2369/4885UCHL1 3265/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | NR1H2 2154/4885SRC 1/4885UCHL1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.